




Contents lists available at ScienceDirect

# Respiratory Physiology & Neurobiology

journal homepage: [www.elsevier.com/locate/resphysiol](http://www.elsevier.com/locate/resphysiol)



## The DL<sub>NO</sub>/DL<sub>CO</sub> ratio: Physiological significance and clinical implications

J.M.B. Hughes<sup>a</sup>, A.T. Dinh-Xuan<sup>b,\*</sup>

<sup>a</sup> National Heart and Lung Institute, Imperial College, London, United Kingdom

<sup>b</sup> Department of Physiology, Cochin Hospital, Assistance Publique, Hôpitaux de Paris, Medical School, Paris Descartes University, Paris, France

### ARTICLE INFO

#### Article history:

Received 18 October 2016  
Received in revised form  
21 December 2016  
Accepted 4 January 2017  
Available online xxx

#### Keywords:

Diffusing capacity  
Transfer factor  
Carbon monoxide  
Nitric oxide  
Lung function  
Gas exchange

### ABSTRACT

DL<sub>NO</sub>/DL<sub>CO</sub> directly measures the ratio of the diffusing capacities of the lung for nitric oxide (NO) and carbon monoxide (CO). In terms of the Roughton and Forster (1957) equation,  $1/DL = 1/Dm + 1/\theta Vc$ , where Dm is the membrane (Dm) and  $\theta Vc$  is the red cell component of the overall diffusing conductance (DL); DL<sub>NO</sub> mostly reflects the Dm component and DL<sub>CO</sub> the  $\theta Vc$  red cell component.

The DL<sub>NO</sub>/DL<sub>CO</sub> ratio is positively related to the Dm<sub>CO</sub>/Vc ratio and the CO red cell resistance ( $1/\theta COVc$ ) as a percentage of the total resistance ( $1/DL_{CO}$ ), independent of the absolute values of DL<sub>NO</sub> or DL<sub>CO</sub>.

In clinical studies, a raised DL<sub>NO</sub>/DL<sub>CO</sub> ratio ( $\geq 110\%$  predicted versus a control group), plus a low DL<sub>NO</sub> and DL<sub>CO</sub> (<67% pred), predicts pulmonary vascular disease, while a low DL<sub>NO</sub>/DL<sub>CO</sub> ratio, with similarly reduced DL<sub>NO</sub> and DL<sub>CO</sub>, is associated with interstitial lung disease with fibrosis. More clinical studies are needed, and reference values need to be better defined.

© 2017 Elsevier B.V. All rights reserved.

### 1. Introduction

In the clinical setting, the diffusing capacity of the lung (DL) is usually measured with the single breath carbon monoxide (CO) uptake technique (DL<sub>CO</sub>). The method has undergone little change since the original description (Ogilvie et al., 1957). In 1983–9, the measurement of diffusing capacity using a different haemoglobin (Hb)-reactive gas, nitric oxide (NO), was introduced (Guénard et al., 1987; Borland and Higenbottam, 1989), employing the same single breath technique. Both tracer gases (CO and NO) were inhaled from the same reservoir (together with an inert volume-marker gas, usually helium). The ratio of DL<sub>NO</sub> to DL<sub>CO</sub> in normal subjects was about 5.0 (Borland and Higenbottam, 1989). This fivefold ratio is caused by the different properties of NO versus CO, as they traverse the blood-gas barrier; the greatest difference lies in the more rapid (about 300 fold) uptake rate of NO versus CO by intracapillary haemoglobin.

It is too early to say whether the DL<sub>NO</sub> will replace the DL<sub>CO</sub> as the best test of the diffusing capacity of the lung. At the present time, measurement of the DL<sub>NO</sub> is always accompanied by a simultaneous DL<sub>CO</sub> measurement. In this article, we will review the physiological processes responsible for the fivefold difference in

the NO-CO uptake rates, and consider the clinical implications of an abnormally high or low DL<sub>NO</sub>/DL<sub>CO</sub> ratio.

### 2. DL<sub>NO</sub> versus DL<sub>CO</sub>: differences and similarities

The conductance of CO from gas to blood is given by the classical equation (Roughton and Forster, 1957):

$$1/DL_{CO} = 1/Dm_{CO} + 1/\theta_{CO}Vc \quad (1)$$

where  $1/DL_{CO}$  is the lung resistance to CO transfer (the reciprocal of the conductance),  $1/Dm_{CO}$  (the molecular diffusion resistance of the lung membranes – from the surfactant lining layer to the red cell membrane – and  $1/\theta Vc$  is the resistance to CO transfer within the red cell. The sum of the red cell and membrane resistances, which are in series, are the components of the overall resistance,  $1/DL_{CO} \times \theta$  and Vc are defined under Nomenclature. The same equation applies to NO uptake:

$$1/DL_{NO} = 1/Dm_{NO} + 1/\theta_{NO}Vc \quad (2)$$

The molecular diffusive conductance for NO in lung tissue ( $\sim$  tissue solubility/MW<sup>-2</sup>) is 1.97 times that for CO; thus, the Dm<sub>NO</sub>/Dm<sub>CO</sub> ratio, designated  $\alpha$ , is 1.97. The ratio of the red cell conductances for NO versus CO,  $\theta_{NO}/\theta_{CO}$ , on the best available evidence from in vitro and in vivo experiments (Guénard et al., 2016), at an alveolar PO<sub>2</sub>  $\sim$  100 mmHg, is 4.5/0.56 = 8.01.  $\theta_{CO}$  is O<sub>2</sub>-sensitive, but  $\theta_{NO}$  is essentially O<sub>2</sub>-insensitive (Borland and Cox, 1991).

\* Corresponding author.

E-mail addresses: [mike.hughes@imperial.ac.uk](mailto:mike.hughes@imperial.ac.uk) (J.M.B. Hughes), [anh-tuan.dinh-xuan@aphp.fr](mailto:anh-tuan.dinh-xuan@aphp.fr) (A.T. Dinh-Xuan).

<http://dx.doi.org/10.1016/j.resp.2017.01.002>

1569-9048/© 2017 Elsevier B.V. All rights reserved.

**Nomenclature**

$DL_{NO}$	Diffusing capacity of the lung for inhaled nitric oxide (NO) in tracer quantities; the units are those of a conductance: $mL\ min^{-1}\ mmHg^{-1}$ (traditional) and $mmol\ min^{-1}\ kPa^{-1}$ (SI), also known as the transfer factor of the lung for nitric oxide $TL_{NO}$ . $1/DL_{NO}$ is the transfer or diffusing capacity resistance
$DL_{CO}$	the same as for $DL_{NO}$ , but with carbon monoxide (CO) replacing NO
$Dm_{CO}$ and $Dm_{NO}$	Membrane diffusing capacity for CO and NO
$\alpha$	$Dm_{NO}/Dm_{CO} = 1.97$
$\theta_{CO}$ and $\theta_{NO}$	Specific conductance for CO and NO transfer within the red cell: units are mL of CO or $NO\ min^{-1}\ mmHg^{-1}$ per mL blood
$1/\theta_{CO}$ and $1/\theta_{NO}$	Specific resistances to transfer
$\Psi$	$\theta_{NO}/\theta_{CO}$ ratio
Vc	The pulmonary capillary volume accessed by inhaled CO and NO
TLC	Total lung capacity
FRC	Functional residual capacity
MW	Molecular weight

Combining Eqs. (1) and (2) with  $\alpha = Dm_{NO}/Dm_{CO} = 1.97$  and  $\theta_{NO}/\theta_{CO} = \Psi = 8.01$ , and assuming [Hb] concentration is 100% predicted:

$$Vc = [(1/\theta_{CO}) \cdot (1 - \alpha/\Psi)] / (1/DL_{CO} - \alpha/DL_{NO}) \quad (3)$$

$$Dm_{CO} = (1/\alpha - 1/\Psi) / [(1/DL_{NO}) - 1/(\Psi \cdot DL_{CO})] \quad (4)$$

In Sections 4 and 5, we have used Eqs. (3) and (4) to explore the relationship between  $DL_{NO}/DL_{CO}$  and two ratios for CO diffusion derived from Eq. (1): a) the membrane conductance – pulmonary capillary volume ratio ( $Dm_{CO}/Vc$ ) –  $\theta_{CO}$  breathing air, is essentially constant—and b) the red cell resistance to CO diffusion ( $1/\theta_{CO}Vc$ ) as a percentage of the total CO diffusion resistance ( $1/DL_{CO}$ ), ~  $Rrc/Rtot\%$ , which is calculated as  $[1 - (DL_{CO}/Dm_{CO})]\%$ , calculating  $Dm_{CO}$  and Vc from given values of  $DL_{NO}$  and  $DL_{CO}$  (see Fig. 1, Tables 1, 2, and 3).

Eqs. (3) and (4) represent the consensus view at the present time. Nevertheless, some believe that estimates of  $\theta_{NO}$  in vitro grossly underestimate the red cell conductance in vivo. According to this view,  $\theta_{NO}$  in vivo approaches infinity, so that Eq. (2) can be rewritten:

$$1/DL_{NO} = 1/Dm_{NO} = 1/\alpha Dm_{CO} \quad (5)$$

**2.1. A finite versus an infinite value for  $\theta_{NO}$**

In oxygenated blood, NO reacts very rapidly with HbO<sub>2</sub> to form methaemoglobin and nitrate (NO<sub>3</sub>). CO displaces O<sub>2</sub> from HbO<sub>2</sub> at a much slower rate (300 times slower than the NO reaction). But, when the reaction rates are measured in red cell suspensions (rather than cell-free Hb solutions) in vitro, the ratio  $\theta_{NO}/\theta_{CO}$  ( $\Psi$ ) is 8 not 300. There are objections that the red cell  $\theta$  may be an underestimate because of the presence of a layer of plasma (a “stagnant” pool) surrounding each cell. While everyone agrees on the basis of many studies in different species (Borland et al., RPNB this issue, 2017) that  $\theta_{NO}$  in vitro is finite, confirmation that  $\theta_{NO}$  in vivo is finite is harder to obtain. On the other hand, in anaesthetized dogs, an exchange transfusion of red cells for a cell-free blood substitute (bovine Hb-glutamer-200), giving NO more open access to the Hb molecule, increased  $DL_{NO}$  by  $57 \pm 16\%$  and the  $DL_{NO}/DL_{CO}$  ratio from 4.5 to 7.1,  $DL_{CO}$  being unchanged (Borland et al., 2010).

**2.2.  $\theta_{NO}$  and  $\theta_{CO}$  and absolute values of  $Dm_{CO}$  and Vc**

Using Eq. (1) only (the classical method, measuring  $DL_{CO}$  at normal and hyperoxic alveolar PO<sub>2</sub>), estimates of  $Dm_{CO}$  in normal subjects at rest are in the range 40–60  $mL\ min^{-1}\ mmHg^{-1}$  (Hughes and Bates, 2003), rising to 130–180 with combined NO and CO inhalation using Eqs. (3) and (4) and a finite value for  $\theta_{NO}$  (Zavorsky et al., 2017). Vc goes in the opposite sense, from 80 to 100 mL with the hyperoxic  $DL_{CO}$  to 65–85 mL with the combined  $DL_{NO}-DL_{CO}$  measurement. If an infinite  $\theta_{NO}$  is taken, so that  $Dm_{CO} = 0.5 DL_{NO}$  (Eq. (5)), estimated  $Dm_{CO}$  falls and Vc rises towards the values found with the classical  $DL_{CO}$  multi-step O<sub>2</sub> technique. The higher values of  $Dm_{CO}$ , using the NO-CO analysis and a finite  $\theta_{NO}$ , are more in line, particularly on exercise ( $Dm_{CO} \sim 260\ mL\ min^{-1}\ mmHg^{-1}$  (Zavorsky et al., 2004)) with morphometric measurements (representing the theoretical maximum values) of  $280\ mL\ min^{-1}\ mmHg^{-1}$  (Gehr et al., 1978). This concordance of physiologic with morphometric values for  $Dm_{CO}$  is some justification, albeit indirect, for the use of the simultaneous NO-CO inhalation technique, coupled with a finite value for  $\theta_{NO}$ . But, the issue of finite versus infinite  $\theta_{NO}$  is still a matter for debate.

**3.  $DL_{NO}/DL_{CO}$  ratio: physiological interpretation**

With the classical analysis (Eq. (1)), the resistance split between  $1/Dm_{CO}$  and  $1/\theta_{CO}Vc$  was about 50:50 (Hsia et al., 1995). On clinical grounds, the  $DL_{CO}$  data from pulmonary vascular disease and anaemia seemed to favour a 25:75 partition between the membrane resistance,  $1/Dm_{CO}$  (25%) and the red cell resistance,  $1/\theta_{CO}Vc$  (75%), and this was supported by calculations of  $Dm_{CO}$  and Vc, using more recent estimates (Forster, 1987) of the  $1/\theta_{CO} - PO_2$  relationship (Hughes and Bates, 2003). Recent work using the NO-CO method with finite values for  $\theta_{NO}$  (and, of course,  $\theta_{CO}$ ) suggest that the red cell resistance percentage for  $1/DL_{NO}$  is much less (c.37%), and that  $1/DL_{NO}$  is dominated by the membrane resistance (63%) (Borland et al., 2010). In simple terms,  $1/DL_{NO}$  represents  $1/(Dm_{CO}1.97)$ , and  $1/DL_{CO}$  reflects  $1/Vc$ ; thus,  $DL_{NO}/DL_{CO}$  is an expression of two related ratios,  $Dm_{CO}/Vc$  and the  $Rrc/Rtot\%$  fraction for CO (Fig. 1, Table 1).


**4. Relationship between  $DL_{NO}/DL_{CO}$  and  $Dm_{CO}/Vc$**

For this analysis, we have computed theoretical  $DL_{NO}$ ,  $DL_{CO}$  and  $DL_{NO}/DL_{CO}$  values in terms of Eqs. (3) and (4) using the generally accepted value for  $\theta_{NO}$  (Carlsen and Comroe, 1958) and a newly published equation for the  $1/\theta_{CO}-PO_2$  relationship based on both in vitro and in vivo data (Guénard et al., 2016). Fig. 1 shows a curvilinear relationship between  $Dm_{CO}/Vc$  and  $DL_{NO}/DL_{CO}$ , which is independent of the absolute values of  $DL_{NO}$  and  $DL_{CO}$ , as shown in Table 1. Thus, on the basis of  $Dm_{NO}/Dm_{CO}$  of 1.97 ( $\alpha$ ) and  $\theta_{NO}/\theta_{CO}$  ( $\Psi$ ) of 8.01,  $Dm_{CO}/Vc$  can be predicted from the  $DL_{NO}/DL_{CO}$  ratio.  $Rrc/Rtot\%$  behaves similarly to  $Dm_{CO}/Vc$ .

**5.  $DL_{NO}/DL_{CO}$  ratio in health and disease**

**5.1. Normal values**

In the period 2007–8, three groups published reference values for  $DL_{NO}$  in European (van der Lee et al., 2007; Aguilaniu et al., 2008) and North American (Zavorsky et al., 2008a,b) adult populations. There were some important differences. The subjects in the North American study were younger and more athletic; two studies used the less sensitive electrochemical cell for NO analysis and a breath hold time (BHT) of 4 s (Aguilaniu et al., 2008) and 5.5 s (Zavorsky et al., 2008a,b), and one a high sensitivity chemilumines-



**Fig. 1.** Ratio of carbon monoxide (CO) membrane diffusing capacity ( $Dm_{CO}$ ) to pulmonary capillary volume ( $V_c$ ),  $Dm_{CO}/V_c$ , and red cell diffusion resistance ( $Rrc$ ) for CO as a percentage of total ( $R_{tot}$ ) CO diffusion resistance,  $Rrc/R_{tot}\%$ , plotted against ratio of diffusing capacities for nitric oxide (NO) and CO ( $DL_{NO}/DL_{CO}$ ) for normal male, aged 45 years, height 175 cm. Individual points calculated using Eqs. (3) and (4), and the computer programme in the on-line supplement of [Zavorsky et al. \(2017\)](#). The relationship is given by the equation  $Dm_{CO}/V_c = 0.0536 \cdot \exp^{0.7465 \cdot DL_{NO}/DL_{CO}}$  and  $Rrc/R_{tot}\% = 69.805 \ln(DL_{NO}/DL_{CO}) - 31.963$ .

**Table 1**

Computations, using Eqs. (3) and (4) with  $\theta_{NO}$  and  $\theta_{CO}$  from [Guénard et al. \(2016\)](#), at constant  $DL_{NO}/DL_{CO}$  ratios (High, Normal and Low), showing that the  $Dm_{CO}/V_c$  ratio and red cell diffusion resistance for CO as percent total diffusion resistance ( $Rrc/R_{tot}\%$ ) do not depend on absolute values of  $DL_{NO}$  and  $DL_{CO}$ , only on the  $DL_{NO}/DL_{CO}$  ratio. All values except  $Dm_{CO}/V_c$  are as percent predicted normal for male aged 45 years, height 1.75 m (from on-line supplement, [Zavorsky et al., 2017](#))<sup>a</sup>.

$DL_{NO}/DL_{CO}$	$DL_{NO} \%$	$DL_{CO} \%$	$Dm_{CO} \%$	$V_c \%$	$Dm_{CO}/V_c$	$Rrc/R_{tot}\%$
HIGH						
5.99	100	83	153	70	4.53	89
6.0	85	70	131	59	4.55	89
NORMAL						
4.85	110	113	108	108	2.07	79
4.85	70	72	69	69	2.08	79
LOW						
3.5	84	119	58	156	0.77	58
3.5	51	72	35	94	0.77	58

$Dm_{CO}$ : membrane diffusing capacity for carbon monoxide.

$V_c$ : pulmonary capillary volume.

<sup>a</sup> 100% predicted = 166 (DLNO), 33.5 (DLCO), 166 (DmCO) 75 (Vc), 2.22 (DmCO/Vc), 80 (Rrc/Rtot%): units are  $mL \cdot min^{-1} \cdot mmHg^{-1}$ , except for Vc (mL) and  $Dm_{CO}/V_c$  and  $Rrc/R_{tot}$  (dimensionless).

**Table 2**

Effects of acute and chronic exposure to the hypoxia of altitude in healthy lowlanders and highlanders, except for one study of highlanders with chronic mountain sickness (CMS). All results are as % of sea level controls for each study. Values <90% > 110% are in bold-italic.  $Dm_{CO}$  and  $V_c$  computed from  $DL_{NO}$  and  $DL_{CO}$  using Eqs. (3) and (4).

Authors	Subjects	n	Altitude exposure	$DL_{NO}/DL_{CO}$	$DL_{NO} \%$	$DL_{CO} \%$	$Dm_{CO} \%$	$V_c \%$
A.1 <a href="#">Martinot et al. (2013)</a>	Lowlanders	25	2–3 days at 4300 m. Peru.	92	<b>121</b>	<b>131</b>	108	<b>138</b>
B.1 <a href="#">Faoro et al. (2014)</a>	Lowlanders	13	2–4 days at 5,0050 m. Nepal.	93	103	<b>112*</b>	94	<b>120</b>
C.1 <a href="#">de Bisschop et al. (2010)</a>	Lowlanders	16	4 days at 4000 m. Bolivia.	<b>86</b>	<b>84</b>	97*	73	<b>111</b>
D.1 <a href="#">Groepenhoff et al. (2012)</a>	Lowlanders	15	4 days at 4300 m. Peru.	<b>83</b>	<b>127</b>	<b>155</b>	102	<b>183</b>
A.2 <a href="#">Martinot et al. (2013)</a>	Lowlanders	25	7–8 days. 4300 m	100	107	107	108	107
E. <a href="#">Taylor et al. (2016)</a>	Lowlanders	7	40 days at 5150 m. Nepal.	106	<b>117</b>	110	<b>126</b>	104
C.2 <a href="#">de Bisschop et al. (2010)</a>	Highlanders	8	4000 m. Bolivia.	<b>83</b>	110	<b>133</b>	<b>129</b>	<b>161</b>
B.2 <a href="#">Faoro et al. (2014)</a>	Highlanders	28	5150 m. Nepal	<b>82</b>	<b>153</b>	<b>185</b>	<b>125</b>	<b>222</b>
D.2 <a href="#">Groepenhoff et al. (2012)</a>	Highlanders	15	4300 m. Peru.	<b>79</b>	<b>132</b>	<b>167</b>	101	<b>208</b>
D.3 <a href="#">Groepenhoff et al. (2012)</a>	Highlanders with CMS	13	4300 m. Peru.	<b>77</b>	<b>148</b>	<b>194</b>	110	<b>253</b>
						(Hb 24.0)		<b>(154*)</b>

\* Corrected for polycythaemia to the standard haemoglobin level (13.4–14.6 g dL<sup>-1</sup>).

**Table 3**  
Clinical studies of DL<sub>NO</sub>/DL<sub>CO</sub> ratios with related values and indices. All values are as percent of study controls. Dm<sub>CO</sub>/Vc, Dm<sub>CO</sub> and Vc were computed for patients and controls using Eqs. (3) and (4), and expressed as % of study controls. Bold italic  $\leq$  two-thirds (67%) of control. Rows arranged in descending order of DL<sub>NO</sub>/DL<sub>CO</sub> ratios (% control) and in three sections (A > 110%, B  $\leq$  110%  $\geq$  95%, C < 95%).

Authors	Diagnosis	N <sup>1</sup>	DL <sub>NO</sub> /DL <sub>CO</sub>	DL <sub>NO</sub> %	DL <sub>CO</sub> %	Dm <sub>CO</sub> /Vc	Dm <sub>CO</sub> %	Vc%
<b>GROUP A</b>								
van der Lee et al. (2006)	PAH <sup>2</sup>	26	114	<b>58</b>	<b>65</b>	148	<b>69</b>	<b>40</b>
Borland et al. (1996)	PAH <sup>3</sup>	12	111	<b>65</b>	<b>62</b>	143	82	<b>57</b>
Degano et al. (2009)	HPS <sup>4</sup>	11	111	71	<b>66</b>	127	80	<b>63</b>
<b>GROUP B</b>								
van der Lee et al. (2009)	COPD: GOLD 1 <sup>5</sup>	68	110	95	86	110	95	86
van der Lee et al. (2009)	Smokers: GOLD 0 <sup>6</sup>	168	107	95	89	118	102	86
Magini et al. (2015)	CHF <sup>7</sup>	50	107	82	77	126	88	74
van der Lee et al., 2006	ILD <sup>8</sup>	41	105	<b>58</b>	<b>65</b>	117	<b>62</b>	<b>52</b>
Zavorsky et al. (2008a,b)	Morbid obesity	10	103	108	95	86	95	111
Farha et al. (2013)	PAH <sup>3</sup>	28	100	70	71	97	70	71
van der Lee et al. (2009)	COPD: GOLD 2 <sup>5</sup>	26	97	88	86	91	80	89
<b>GROUP C</b>								
Moinard and Guénard (1990)	COPD: GOLD 3–4 <sup>5</sup>	10	94	<b>52</b>	<b>56</b>	82	<b>48</b>	<b>59</b>
Barisione et al. (2016)	NSIP <sup>9</sup>	30	91	<b>52</b>	<b>58</b>	70	<b>45</b>	<b>64</b>
Barisione et al. (2016)	UIP–ILD <sup>10</sup>	30	89	<b>32</b>	<b>37</b>	<b>63</b>	<b>27</b>	<b>42</b>
Barisione et al. (2014)	BMT <sup>11</sup>	40	87	70	80	68	<b>62</b>	72
Dressel et al. (2009)	Cystic fibrosis	21	86	77	87	68	<b>67</b>	99
Phansalkar et al. (2004)	ILD <sup>8</sup> (sarcoidosis)	25	80	<b>35</b>	<b>43</b>	<b>52</b>	<b>28</b>	<b>54</b>


<sup>1</sup> number of patients in each study.  
<sup>2</sup> pulmonary artery hypertension, 77% of whom had chronic thromboembolic disease.  
<sup>3</sup> idiopathic peripheral pulmonary arterial hypertension.  
<sup>4</sup> hepatopulmonary syndrome based on arterial hypoxaemia and positive contrast-enhanced echocardiography.  
<sup>5</sup> GOLD staging of COPD severity (FEV<sub>1</sub>/FVC < 0.7). GOLD 1 = FEV<sub>1</sub>% predicted  $\geq$  80%; GOLD 2 = FEV<sub>1</sub>% predicted < 80%; GOLD 3–4 = FEV<sub>1</sub>% predicted < 50%.  
<sup>6</sup> GOLD 0: asymptomatic smokers without airflow obstruction (FEV<sub>1</sub>/FVC > 0.7).  
<sup>7</sup> chronic heart failure.  
<sup>8</sup> diffuse interstitial lung disease with fibrosis.  
<sup>9</sup> non-specific interstitial pneumonia, associated with inflammation and fibrosis.  
<sup>10</sup> usual interstitial pneumonia with lung fibrosis.  
<sup>11</sup> patients selected for bone marrow transplantation for haematological malignancies.

cence analyser with the conventional 10 s BHT (van der Lee et al., 2007). Thus, differences exist in a “standard” value for DL<sub>NO</sub>, DL<sub>CO</sub> and DL<sub>NO</sub>/DL<sub>CO</sub> for these studies. For example, for a healthy male, aged 45 years, height 1.75 m, DL<sub>NO</sub> varies from 143 (van der Lee et al., 2007) to 175 (Aguilaniu et al., 2008) mL min<sup>-1</sup> mmHg<sup>-1</sup>, and the DL<sub>NO</sub>/DL<sub>CO</sub> ratio varies from 4.4 (van der Lee et al., 2007) to 5.16 (Zavorsky et al., 2008a,b). In clinical studies (Tables 2 and 3), where the number of healthy controls is very much less, mean DL<sub>NO</sub> for each control group varied from 89 to 178 mL min<sup>-1</sup> mmHg<sup>-1</sup> and mean group DL<sub>NO</sub>/DL<sub>CO</sub> from 3.9 to 5.44.

Nevertheless, the ERS Task Force on DL<sub>NO</sub> standardisation (Zavorsky et al., 2017) has analysed the individual results for 490 Caucasian subjects from the three studies mentioned (67 outliers including 22 non-Caucasians were excluded) and produced combined reference equations for DL<sub>NO</sub>, DL<sub>CO</sub>, VA, K<sub>NO</sub> and K<sub>CO</sub>. From the combined data, reference values for Dm<sub>CO</sub>, Dm<sub>CO</sub>/Vc and Vc were calculated using the best available values for  $\theta_{NO}$  and  $\theta_{CO}$  (Guénard et al., 2016); these reference values have been used in the percent predicted estimates in Table 1, and in the calculation of Dm<sub>CO</sub> and Vc, Dm<sub>CO</sub>/Vc in Figs. 1 and 2, and Tables 2 and 3. No predictions were possible for the DL<sub>NO</sub>/DL<sub>CO</sub> ratio, since age<sup>2</sup>, height and sex contributed less than 5% to the variance. Thus, for clinical studies (Tables 2 and 3) the group mean DL<sub>NO</sub>/DL<sub>CO</sub> has been referenced to the group mean DL<sub>NO</sub>/DL<sub>CO</sub> of locally sourced healthy controls.

5.2. Ageing

It is well known that DL<sub>NO</sub> and DL<sub>CO</sub> decline with increasing age. This is due to the K<sub>CO</sub> (or K<sub>NO</sub>) component of DL (=VA·K), not the VA component. Since VA is common to DL<sub>NO</sub> and DL<sub>CO</sub>, the effects of ageing on DL<sub>NO</sub>/DL<sub>CO</sub> should depend on the rate of change in the K<sub>NO</sub>/K<sub>CO</sub> ratio. Hughes and van der Lee (2013) found essentially no change in DL<sub>NO</sub>/DL<sub>CO</sub> which is in agreement with later anal-



**Fig. 2.** Plot of diffusing capacities for nitric oxide (NO) and carbon monoxide (CO) and their ratio (DL<sub>NO</sub>/DL<sub>CO</sub>), membrane diffusing capacity for carbon monoxide (Dm<sub>CO</sub>), and the Dm<sub>CO</sub>–pulmonary capillary volume ratio (Dm<sub>CO</sub>/Vc) (on the ordinate) versus alveolar volume (~lung volume minus anatomic dead space) as % maximum (~TLC minus dead space) while normal subjects voluntarily changed lung expansion (50% VA max is about FRC). Note DL<sub>NO</sub>, Dm<sub>CO</sub> and Dm<sub>CO</sub>/Vc are more volume sensitive than DL<sub>CO</sub> itself, implying that Vc is independent of lung expansion change, and that DL<sub>CO</sub> is relatively independent, due to the influence of Vc. The Figure was reproduced from Zavorsky et al. (2017), and data were derived from van der Lee et al. (2007) and Hughes and van der Lee (2013).

yses (Zavorsky et al., 2017). Age independence is a benefit when DL<sub>NO</sub>/DL<sub>CO</sub> ratios in the elderly are being considered.

### 5.3. Exercise

The ERS–ATS Task Force (Zavorsky et al., 2017) has reviewed  $DL_{NO}$  exercise studies.  $DL_{NO}$  and  $DL_{CO}$  increase linearly as cardiac output and oxygen consumption increase, but with more scatter for the  $DL_{NO}$  relationship. With exercise, pulmonary vascular pressures increase and more alveolar surface is available for gas exchange from the opening up of closed capillary units in the alveolar septa (recruitment) and dilatation of already patent vessels. This recruitment and dilation increases  $Dm_{NO}$  and  $Dm_{CO}$  (“more” membrane now takes part in NO and CO transfer). In addition,  $DL_{CO}$  will increase as capillary volume ( $V_c$ ) increases (this will be a smaller effect for  $DL_{NO}$ ). As a result, the  $DL_{NO}/DL_{CO}$  ratio decreases linearly with increasing power output (Tamhane et al., 2001) by about 17–28% from rest to maximum exercise, or by 0.06 units for each  $1.0 L \text{ min}^{-1}$  increase in cardiac output (Zavorsky et al., 2007). In sarcoidosis with parenchymal fibrosis, the  $DL_{NO}/DL_{CO}$  ratio fell similarly from rest to exercise (Phansalkar et al., 2004).

### 5.4. Change in lung expansion ( $\Delta VA$ )

In healthy subjects,  $DL_{NO}$  and  $DL_{CO}$  are measured at maximum inflation, i.e. at a breath hold at total lung capacity (TLC). In the single breath test, this breath hold lung volume is measured by inert gas dilution from gas expired after the breath hold. A subtraction of “non-gas exchanging” volume is made (instrumental plus anatomic dead space) and an “alveolar volume” (VA) calculated. This VA at TLC ( $\sim VA_{max}$ ) is about 94% (SD 7%) of a separately measured TLC by multi-breath dilution (Roberts et al., 1990; van der Lee et al., 2007); this difference (from 100%) is 3–4% greater than expected from the anatomic dead space, and reflects incomplete alveolar mixing in the 10 s breath hold time.

Normal subjects can voluntarily stop the initial inspiration to TLC at a submaximal volume ( $VA_{50\%max}$  to  $VA_{90\%max}$ ) and  $DL_{NO}$  and  $DL_{CO}$  and their components measured at different levels of alveolar expansion (van der Lee et al., 2007). In Fig. 2, as the alveoli reduce in size (down to 50%  $VA_{max}$ ), the reduction in  $DL_{NO}$  exceeds that of  $DL_{CO}$  and the  $DL_{NO}/DL_{CO}$  ratio falls. This is because  $\Delta DL_{NO}$  is more driven by  $\Delta Dm_{NO}$  than the more  $V_c$ -weighted  $DL_{CO}$ .  $V_c$  changes little as the lung becomes smaller; for example, the change in  $Dm_{CO}/V_c$  is almost the same as the change in  $Dm_{CO}$  itself. In the clinical setting, extrapulmonary restriction which reduces VA to 50% max should reduce the  $DL_{NO}/DL_{CO}$  ratio to 80% predicted.

### 5.5. Implication for $DL_{NO}/DL_{CO}$ if VA is reduced other than by expansion loss

VA can be reduced by alveolar destruction or filling with fluid or inflammatory tissue. This may be local (e.g. pneumonectomy) or diffuse. A 50% loss of VA in pneumonectomy results in a  $DL_{CO}$  of 60% of predicted max, not 50%, because the blood flow and volume per unit alveolar volume in the remaining lung increases  $DL_{CO}$  by capillary dilatation and recruitment (Hughes and Pride, 2012). This “compensatory” effect (mediated by an increase in  $K_{CO}$  to 110–120% predicted) might be less for  $DL_{NO}$  (though  $DL_{NO}$  is also blood volume sensitive), so  $DL_{NO}/DL_{CO}$  might fall; there is no data one way or the other. A third cause of VA reduction is poor distribution of the inhaled marker gases; this occurs in airflow obstruction when the separately measured TLC exceeds the single breath VA. The effect on  $DL_{NO}/DL_{CO}$  is difficult to predict.

### 5.6. $DL_{NO}/DL_{CO}$ ratios in altitude-induced hypoxia

There have been several studies of the effects of acute and chronic exposure to the hypoxia of altitude dwelling (summarised in Table 2). All values, including those for permanent residents (highlanders) are expressed as percent of that at sea level in the

“lowlanders”. Except for study A.2 (Table 2) the effect of acute (2–4 days) altitude exposure (rows A.1, B.1, C.1, D.1) is a fall in  $DL_{NO}/DL_{CO}$ , but the changes in the various components in Table 2 are more variable; the most consistent change is a rise in  $V_c$ , probably due to an increase in cardiac output and pulmonary capillary recruitment and dilatation. After 40 days exposure (study E),  $V_c$  appears to have returned to the sea level value, but this is only a single study. In a comparison of lowlanders and highlanders (acute versus chronic exposure) – B.1–2, C.1–2 and D.1–2 – highlanders have large increases in  $DL_{NO}$ ,  $DL_{CO}$ ,  $Dm_{CO}$  and  $V_c$ , with reductions in  $DL_{NO}/DL_{CO}$ . Highlanders have secondary polycythaemia, which is particularly marked in those with chronic mountain sickness (CMS) – D.3. The high haemoglobin explains a large part of the high  $DL_{CO}$  and  $V_c$ .

The main changes are probably a) an increase in pulmonary blood flow ( $\sim$ cardiac output) on acute exposure (high  $DL_{NO}$ ,  $DL_{CO}$  and  $V_c$ ) and b) secondary polycythaemia increasing  $DL_{CO}$  and  $V_c$  with chronic (lifelong) exposure through an expansion of the alveolar membrane surface ( $\uparrow Dm_{CO}$  in 2/3 studies); interestingly, Faoro et al. (2014) reported an increased VA in highlanders, as did Martinot et al. (2013) in 2/3 day exposure in lowlanders. Capillary recruitment ( $\uparrow DL_{CO}$  and  $\uparrow V_c$ ) must also occur.

### 5.7. $DL_{NO}/DL_{CO}$ ratios in pulmonary and cardiac disease

Most of the clinical studies to date are listed in Table 3. Each study had their own controls (normal subjects) and all patient values are reported as “% control”. This is important because, at this early stage in the development of the  $DL_{NO}$ , the “control”  $DL_{NO}/DL_{CO}$  varies widely from study to study (from 3.9 to 5.4).

In Table 3 (Group A), high  $DL_{NO}/DL_{CO}$  ( $>110\%$  control) ratios plus  $DL_{CO}$  and/or  $DL_{NO}$  values  $<67\%$  predicted normal are associated with pulmonary vascular disease, either pulmonary arterial hypertension or the pulmonary capillary remodelling and dilatation of the hepatopulmonary syndrome (HPS). In all three studies,  $DL_{NO}$  and  $DL_{CO}$  values are low, but the  $Dm_{CO}/V_c$  ratio is high. The reduction in  $V_c$  is greater than the reduction in the membrane conductance ( $Dm_{CO}$ ).

In Group B (Table 3),  $DL_{NO}/DL_{CO}$  ratios are normal (110–97% control). Those studies with a reduced  $DL_{CO}$  ( $<80\%$  control) are also associated with pulmonary hypertension, either arterial (Farha et al., 2013) or venous hypertension (chronic heart failure, Magini et al., 2015). The Magini et al. (2015) study ( $Dm_{CO}$  and  $V_c$  have been recalculated via the on-line supplement in Zavorsky et al., 2017) is interesting because the reduction in  $V_c$  is greater than the reduction in  $Dm_{CO}$ . In previous studies, using the normoxic–hyperoxic  $DL_{CO}$  analysis, the opposite has been found (Puri et al., 1995). The van der Lee et al. (2006) study in ILD will be discussed later.

In Group C, a low  $DL_{NO}/DL_{CO}$  ( $<95\%$  control) was seen in destructive lung disease. Where the  $DL_{CO}$  and/or  $DL_{NO}$  values were  $<67\%$  predicted normal (or, for Barisione et al., 2014; Dressel et al., 2009, where only the  $Dm_{CO}$  was  $\leq 67\%$  predicted), the pathological process was (in 4/6 examples) interstitial lung disease with diffuse fibrosis, or in one instance (Moinard and Guénard, 1990) destructive emphysema. The study of van der Lee (2006) in ILD (mostly sarcoidosis) with a normal  $DL_{NO}/DL_{CO}$  ratio (Group B), but reduced  $DL_{NO}$  and  $DL_{CO}$ , is an anomaly; the computed  $Dm_{CO}/V_c$  was greater than the  $V_c$ , whereas in the last four studies in Group C (with  $DL_{NO}/DL_{CO} < 95\%$  controls) the opposite was the case. At present, there is no obvious explanation.

In summary, a high  $DL_{NO}/DL_{CO}$  is associated with pulmonary vascular disease and a low  $DL_{NO}/DL_{CO}$  with alveolar destruction (emphysema or fibrosis). The pattern of changes in  $Dm_{CO}/V_c$  (Table 3) and in  $Rrc/Rtot\%$  (data not shown) mirror those of  $DL_{NO}/DL_{CO}$ , but  $Dm_{CO}/V_c$  and  $Rrc/Rtot\%$  are computed variables, whereas  $DL_{NO}/DL_{CO}$  is directly measured.

## 6. Conclusions

1. The ultra-rapid reaction of NO with red cell haemoglobin implies that NO conductance ( $DL_{NO}$ ) from alveolar gas to pulmonary capillary blood mostly measures the alveolar–capillary membrane diffusing capacity ( $Dm$ ), but because of the slower reaction of CO with oxygenated haemoglobin,  $DL_{CO}$  mainly reflects red cell conductance, and will be reduced when pulmonary capillary volume ( $V_c$ ) is compromised.
2. The  $DL_{NO}/DL_{CO}$  ratio, according to the Roughton and Forster (1957) equation, is positively related to the  $Dm_{CO}/V_c$  ratio and to the CO red cell resistance fraction ( $Rrc/R_{tot}$ ) in a curvilinear manner (Fig. 1).
3. The relationship between  $DL_{NO}/DL_{CO}$  and  $Dm_{CO}/V_c$  or  $Rrc/R_{tot}$  is independent of the absolute values of  $DL_{NO}$  or  $DL_{CO}$  (Table 1).
4. The response of lowlanders to acute exposure to high altitude is variable, but there is a trend for a reduced  $DL_{NO}/DL_{CO}$  and a high  $V_c$ , probably due to capillary recruitment. With longer exposure, and in native highlanders, there is secondary polycythaemia, and a larger fall in  $DL_{NO}/DL_{CO}$  and rise in  $V_c$ , even after Hb correction (Table 2).
5. In clinical studies, three patterns emerged for the  $DL_{NO}/DL_{CO}$  ratio: A) high ( $\geq 110\%$  predicted), associated with pulmonary vascular disease, B) normal ( $< 110\%$   $> 95\%$ ) in mild to moderate COPD, chronic heart failure and morbid obesity, C) low ( $\leq 95\%$ ) associated with moderate to severe COPD, cystic fibrosis, but predominantly with interstitial lung disease with fibrosis (Table 3).
6. Because of a wide spread of  $DL_{NO}/DL_{CO}$  values in healthy controls between studies (ranging from 3.9 to 5.4), we recommend each laboratory uses their own healthy controls.

## References

Aguilaniu, B., Maitre, J., Glénet, S., Gegout-Petit, A., Guénard, H., 2008. European reference equations for CO and NO lung transfer. *Eur. Respir. J.* 31, 1091–1097.

Barisione, G., Bacigalupo, A., Brusaco, C., Scanarotti, C., Penco, S., Bassi, A.M., Lamparelli, T., Garlaschi, A., Pellegrino, R., Brusasco, V., 2014. Mechanisms for reduced pulmonary diffusing capacity in haemopoietic stem-cell transplantation recipients. *Respir. Physiol. Neurobiol.* 194, 54–61.

Barisione, G., Brusasco, C., Garlaschi, A., Baroffio, M., Brusasco, V., 2016. Lung diffusing capacity for nitric oxide as a marker of fibrotic changes in idiopathic interstitial pneumonias. *J. Appl. Physiol.* 120, 1029–1038.

Borland, C.D., Higenbottam, T.W., 1989. A simultaneous single breath measurement of pulmonary diffusing capacity with nitric oxide and carbon monoxide. *Eur. Respir. J.* 2, 56–63.

Borland, C.D., Cox, Y., 1991. Effect of varying alveolar oxygen partial pressure on diffusing capacity for nitric oxide and carbon monoxide, membrane diffusing capacity and lung capillary volume. *Clin. Sci.* 81, 759–765.

Borland, C.D., Cox, Y., Higenbottam, T., 1996. *Thorax* 51, 855–856.

Borland, C.D., Dunningham, H., Bottril, F., Vuylsteke, A., Yilmaz, C., Dane, D.M., Hsia, C.C., 2010. Significant blood resistance to nitric oxide transfer in the lung. *J. Appl. Physiol.* 108, 1052–1060.

Borland, C.D., Hughes, J.M.B., Guénard, H., 2017. The blood transfer conductance for CO and NO. *Respir. Physiol. Neurobiol.* (in press).

Carlsen, E., Comroe, J.H., 1958. The rate of uptake of carbon monoxide and of nitric oxide by normal human erythrocytes and experimentally produced spherocytes. *J. Gen. Physiol.* 42, 83–107.

Degano, B., Mittaine, M., Guénard, H., Rami, J., Garcia, G., Kamar, N., Bureau, C., Péron, J.M., Rostaing, L., Rivière, D., 2009. Nitric oxide and carbon monoxide transfer in patient with advanced liver cirrhosis. *J. Appl. Physiol.* 107, 139–143.

Dressel, H., Filser, L., Fisacher, R., Marten, K., Müller-Lisse, U., de la Motte, D., Nowak, D., Huber, R.M., Jörres, R.A., 2009. Lung diffusing capacity for nitric oxide and carbon monoxide in relation to morphological changes as assessed by computed tomography in patients with cystic fibrosis. *BMC Pulm. Med.* 9, 30 (1–7).

de Bisschop, C., Kiger, L., Marden, M.C., Ajata, A., Huez, S., Faoro, V., Martinot, J.B., Naeije, R., Guénard, H., 2010. Pulmonary capillary blood volume and membrane conductance in Andeans and lowlanders at high altitude: a cross sectional study. *Nitric Oxide* 23, 187–193.

Faoro, V., Huez, S., Vanderpool, R., Groepenhoff, H., de Bisschop, C., Martinot, J.B., Lamotte, M., Pavelescu, A., Naeije, R., 2014. Pulmonary circulation and gas exchange at exercise in Sherpas at high altitude. *J. Appl. Physiol.* 116, 919–926.

Farha, S., Laskowski, D., George, D., Park, M.M., Wilson Tang, W.H., Dweik, R.A., Erzurum, S.C., 2013. Loss of alveolar membrane diffusing capacity and capillary blood volume in pulmonary arterial hypertension. *Respir. Res.* 14, 6.

Forster, R.E., 1987. Diffusion of gases across the alveolar membrane. In: *Handbook of Physiology. The Respiratory System. Gas Exchange*, Washington, DC, Am. Physiol. Soc., sect 3, vol IV, chap 5, p. 71–88.

Gehr, P., Bachofen, M., Weibel, E.R., 1978. The normal human lung; ultrastructure and morphometric estimation of diffusing capacity. *Respir. Physiol.* 32, 121–140.

Groepenhoff, H., Overbeek, M.J., Mule, M., van der Plas, M., Argiento, P., Villafuerte, F.C., Beloka, S., Faoro, V., Marcalupo, J.L., Guénard, H., de Bisschop, C., Martinot, J.B., 2012. Exercise pathophysiology in patients with chronic mountain sickness. *Chest* 142, 877–884.

Guénard, H., Varenne, N., Vaida, P., 1987. Determination of lung capillary blood volume and membrane diffusing capacity by measurement of NO and CO transfer. *Respir. Physiol.* 70, 113–120.

Guénard, H., Martinot, J.B., Martin, S., Maury, B., Lalande, S., Kays, C., 2016. In vivo estimates of NO and CO conductance for haemoglobin and for lung transfer in humans. *Respir. Physiol. Neurobiol.* 228, 1–8.

Hsia, C.C., McBrayer, D.G., Ramanathan, M., 1995. Reference values of pulmonary diffusing capacity during exercise by a rebreathing technique. *Am. J. Respir. Crit. Care Med.* 152, 658–665.

Hughes, J.M., Bates, D.V., 2003. Historical review: the carbon monoxide diffusing capacity ( $DL_{CO}$ ) and its membrane (DM) and red cell ( $\Theta \cdot V_c$ ) components. *Respir. Physiol. Neurobiol.* 138, 115–142.

Hughes, J.M., Pride, N.B., 2012. Examination of the carbon monoxide diffusing capacity ( $DL_{CO}$ ) in relation to its  $K_{CO}$  and VA components. *Am. J. Respir. Crit. Care Med.* 186, 132–139.

Hughes, J.M., van der Lee, I., 2013. The TLNO/TLCO ratio in pulmonary function test interpretation. *Eur. Respir. J.* 41, 453–461.

Magini, A., Apostolo, A., Salvioni, E., Italiano, G., Veglia, F., Agostoni, P., 2015. Alveolar–capillary membrane diffusion measurement by nitric oxide inhalation in heart failure. *Eur. J. Prev. Cardiol.* 22, 206–212.

Martinot, J.B., Mule, M., de Bisschop, C., Overbeek, M.J., Le-Dong, N.N., Naeije, R., Guénard, H., 2013. Lung membrane conductance and capillary volume derived from the NO and CO transfer in high-altitude newcomers. *J. Appl. Physiol.* 115, 157–166.

Moinard, J., Guénard, H., 1990. Determination of lung capillary blood volume and membrane diffusing capacity in patients with GOLD using the NOCO method. *Eur. Respir. J.* 3, 318–322.

Ogilvie, C.M., Forster, R.E., Blakemore, W.S., Morton, J.W., 1957. A standardized breath holding technique for the clinical measurement of the diffusing capacity of the lung for carbon monoxide. *J. Clin. Invest.* 36, 1–17.

Phansalkar, A.R., Hanson, C.M., Shakir, A.R., Johnson, R.L., Hsia, C.C., 2004. Nitric oxide diffusing capacity and microvascular recruitment in sarcoidosis. *Am. J. Respir. Crit. Care Med.* 169, 1034–1040.

Puri, S., Baker, B.L., Dutka, D.P., Oakley, C.M., Hughes, J.M., Cleland, J.G., 1995. Reduced alveolar–capillary membrane diffusing capacity in chronic heart failure. Its pathophysiological relevance and relationship to exercise performance. *Circulation* 91, 2769–2774.

Roberts, C.M., Macrae, K.D., Seed, W.A., 1990. Multi-breath and single breath lung volumes as a test of airway obstruction. *Eur. Respir. J.* 3, 515–520.

Roughton, F.J., Forster, R.E., 1957. Relative importance of diffusion and chemical reaction in determining rate of exchange of gases in the human lung. *J. Appl. Physiol.* 11, 290–302.

Tamhane, R.M., Johnson, R.L., Hsia, C.C., 2001. Pulmonary membrane diffusing capacity and capillary blood volume measured during exercise from nitric oxide uptake. *Chest* 120, 1850–1856.

Taylor, B.J., Coffman, K.E., Summerfield, D.T., Issa, A.N., Kasak, A.J., Johnson, B.D., 2016. Pulmonary capillary reserve and exercise capacity at high altitude in healthy humans. *Eur. J. Appl. Physiol.* 116, 427–437.

van der Lee, I., Zanen, P., Grutters, J.C., Snijder, R.J., van den Bosch, J.M., 2006. Diffusing capacity for nitric oxide and carbon monoxide in patients with diffuse parenchymal disease and pulmonary arterial hypertension. *Chest* 129, 378–383.

van der Lee, I., Zanen, P., Stigter, N., van den Bosch, J.M., Lammers, J.W., 2007. Diffusing capacity for nitric oxide: reference values and dependence on alveolar volume. *Respir. Med.* 101, 1579–1584.

van der Lee, I., Gietema, H.A., Zanen, P., van Klaveren, R.J., Prokop, M., Lammers, J.W., van den Bosch, J.M., 2009. Nitric oxide diffusing capacity versus spirometry in the early diagnosis of emphysema in smokers. *Respir. Med.* 103, 1892–1897.

Zavorsky, G.S., Quiron, K.B., Massarelli, P.S., Lands, L.C., 2004. The relationship between single-breath diffusion capacity of the lung for nitric oxide and carbon monoxide during various exercise intensities. *Chest* 125, 1019–1027.

Zavorsky, G.S., Cao, J., Murias, J.M., 2008a. Reference values of pulmonary diffusing capacity for nitric oxide in an adult population. *Nitric Oxide* 18, 70–79.

Zavorsky, G.S., Kim, D.J., Sylvestre, J.L., Christou, N.V., 2008b. Alveolar–membrane diffusing capacity improves in the morbidly obese after bariatric surgery. *Obes. Surg.* 18, 256–263.

Zavorsky, G.S., Hsia, C.C., Hughes, J.M., Borland, C.D., Guénard, H., van der Lee, I., Steenbruggen, I., Naeije, R., Cao, J., Dinh-Xuan, A.T., 2017. Standardization and application of the single-breath determination of nitric oxide uptake in the lung. *Eur. Respir. J.*, <http://dx.doi.org/10.1183/13993003.00926-2016> (in press).